hERGAT:通过原子和分子层面的相互作用分析,利用图形注意力机制预测hERG阻塞剂
1Department of Intelligent Electronics and Computer Engineering, Chonnam National University, Gwangju, Republic of Korea.
Journal of cheminformatics
|January 28, 2025
概括
我们开发了hERGAT,一种使用图表注意力网络 (GAT) 和封闭循环单元 (GRU) 的深度学习模型,用于预测人类以太基因相关基因 (hERG) 通道阻塞. 该模型通过在早期发育中识别心脏毒性化合物来增强药物安全性评估.
科学领域:
- 计算化学和化学信息学
- 药理学和毒理学 药理学和毒理学
- 人工智能在药物发现中的作用
背景情况:
- 人类以太-a-go-go相关基因 (hERG) 通道对心脏电活动至关重要;其阻断剂可以诱导心脏毒性.
- 准确预测hERG通道阻断剂对于药物开发安全至关重要.
- 现有的in silico模型经常在高性能和可解释性方面扎.
研究的目的:
- 为预测hERG通道阻断器开发一种可解释和高性能的in silico模型.
- 利用图形神经网络和注意力机制来分析原子和分子相互作用.
- 提高早期药物安全性评估,降低心脏毒性风险.
主要方法:
- 提出了hERGAT,这是一个图形神经网络模型,包含图形注意力机制 (GAT) 和封闭的反复单位 (GRU).
- 使用GAT分析了原子级相互作用,以整合来自邻近和遥远原子的信息.
- 嵌入了分子级的注意力机制,以识别关键的子结构和集成的物理化学性质.
主要成果:
- 赫尔盖特模型实现了高预测性能,接收器操作特征曲线下的面积为0.907,精度召回曲线下的面积为0.904.
- 注意力机制成功突出了对hERG活动预测至关重要的分子亚结构,文献审查证实了这一点.
- 聚类分析和相关热图验证了模型对遥远的原子相互作用的考虑.
结论:
- hERGAT为预测hERG通道阻塞提供了一个可靠和可解释的框架.
- 该模型捕捉复杂的原子和分子相互作用的能力改善了早期心脏毒性评估.
- 在药物开发的早期阶段,hERGAT显示了优化药物安全的巨大潜力.
相关概念视频
Agonism and Antagonism: Quantification
312
When drugs are administered, they can elicit either an agonist or antagonist effect on the body. Agonism occurs when a drug activates a specific receptor, triggering a biological response. On the other hand, antagonism happens when a drug binds to the same receptors but blocks their activation, thereby preventing a biological response.
To quantify these effects, researchers use a dose-response curve, which provides valuable information about the potency and efficacy of a drug. Potency refers to...
To quantify these effects, researchers use a dose-response curve, which provides valuable information about the potency and efficacy of a drug. Potency refers to...
312
Drug-Receptor Interactions
4.8K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
4.8K
Protein-protein Interfaces
12.4K
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...
12.4K
The Two-State Receptor Model
1.9K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
The binding affinity of a drug determines its interaction with...
1.9K
Ligand-Gated Ion Channel Receptor: Gating Mechanism
2.1K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.1K
Structure-Activity Relationships and Drug Design
493
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
493


